Dr. Afeyan is a recognized technologist and entrepreneur, having founded and helped build several successful life science and technology startups during the past 18 years. A Senior Lecturer at MIT in the Sloan School of Management, as well as the Biological Engineering Division, Dr. Afeyan has authored numerous scientific publications and patents. He earned his PhD in Biochemical Engineering from MIT in 1987.
In 1999, Dr. Afeyan co-founded Flagship Ventures, an early stage venture capital and entrepreneurship firm. Prior to that, he participated in creating and launching six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems (NASDAQ: PBIO), a leader in the bio-instrumentation field. He also served as Chairman of the Board of ChemGenics Pharmaceuticals, a pioneer in genomics-based drug discovery that was a spin-off company of PerSeptive.
After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of their tracking stock subsidiary, Celera Genomics (NYSE: CRA). He has also been a founding team member, investor and active board member/advisor of Antigenics (NASDAQ: AGEN), Color Kinetics (NASDAQ: CLRK) and EXACT Sciences (NASDAQ: EXAS).
Dr. Afeyan currently serves as a Director for Flagship portfolio companies Adnexus Therapeutics, Affinnova, BG Medicine, Bioplex, Codon Devices, Ensemble Discovery, Genstruct, and LS9. He is also engaged as an advisor/board observer with Flagship portfolio companies Epitome Biosystems, Mascoma and Resolvyx. In addition, he is a member of the Boston University Board of Overseers and a member of several advisory boards including the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST) and the Board of Governors of Boston University Medical School. He is also a founder/board member of Armenia 2020, an international economic development project focusing on the former Soviet Republic of Armenia.
Peter Barrett is a Partner in the life sciences group and joined Atlas Venture in 2002.
Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics. Within two years of the founding of the company (1998), Celera announced the first successful sequencing of the human genome. Peter helped launch Celera as a publicly traded entity in 1999. He led Celera's strategic alliances and acquisitions and participated in raising nearly $1 billion in capital for the company.
Prior to Celera, Peter held senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships and acquisitions including: Applied Biosystems, Tropix, Molecular Informatics, PerSeptive Biosystems. Also during this time, Peter co-founded Celera Genomics with Dr. J. Craig Venter and the Applera Corporation management team.
Peter currently serves on the Boards of Atlas portfolio companies Archemix, Aureon, Helicos, Infacare, JenaValve, Molecular Biometrics, Stromedix, Vitae and Zafgen.
Peter is currently Vice Chairman of the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as Adjunct Professor at the Barnett Institute. He also serves as President of the Autism Consortium, a non-profit institution.
Peter received his Bachelor of Science in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his Ph.D. in Analytical Chemistry from Northeastern University. He also completed Harvard Business School's Management Development Program.
Mr. Lowy joined the Helicos Board of Directors in November 2007 and served as the CEO from December 2008 to October 2010. He has more than 30 years of experience managing and growing technology based global businesses.
As president and CEO of Fisher Biosciences, a division of Fisher Scientific, Mr. Lowy was responsible for 14 business units with more than 5,000 employees in 56 locations in 100 countries around the world. Before joining Fisher Biosciences, Mr. Lowy was president of Global Connectivity Solutions for ADC Telecommunications. He also served as president and Chief Operating Officer at the KRONE Group where he was responsible for all facets of this global business unit. Mr. Lowy spent the first 15 years of his career in operations, technology and general management positions at GE Medical Systems where he was intimately involved with the development and commercialization of Computerized Tomography and Magnetic Resonance Systems. Mr. Lowy earned his Master of Business Administration from the University of Wisconsin and a bachelor's of science degree in mechanical engineering from the University of New Hampshire.
Ivan Trifunovich PhD
Executive Chairman, President and Chief Executive Officer
Dr. Trifunovich joined the Helicos Board of Directors as Executive Chairman in September 2010 and was appointed President and Chief Executive Officer in October 2010. He has a proven track record of driving global profitable growth through focused product development and commercialization. Since 2008, Dr. Trifunovich has served as a strategic consultant to global companies in the life sciences industry. Previously, Dr. Trifunovich served as the Senior Vice President of Third Wave Technologies, Inc., a molecular diagnostics company. Prior to joining Third Wave Technologies, Inc., Dr. Trifunovich held successive positions as Vice President of e-Business and Vice President of Research Strategy and Operations at Pharmacia Corp. Prior to joining Pharmacia, Dr. Trifunovich was a Director of New Product Marketing at Johnson & Johnson, Inc. He began his career at Bristol-Meyers Squibb, Inc. as a bench scientist, where he held several positions of increasing responsibility.
Dr. Trifunovich holds a Ph.D. in organic chemistry from UCLA and an M.B.A. from the University of Pennsylvania's Wharton School of Business.
Quotes delayed at least 20 minutes. Information provided by eSignal.
Email alerts sign-up
Fine-tune the emails you receive from Helicos Biosciences Corporation with specific SEC filing types, news types, and stock price changes. Choose to receive the closing stock price each day, or a summary of stock prices at the end of the week.
show all
hide all
